SERIES Move over, genome, transcriptome, proteome. The latest ome aims to map every metabolite linked to human health and disease. Metabolomics, although still a nascent field, offers hope for biomarkers and treatments in neurodegenerative disease. The field
SERIES In the absence of truly effective treatments, and in the presence of a rapidly growing, dementia-prone population of elders, it's perhaps no surprise that people are increasingly open to products claiming even the slightest hint of promise, however u
SERIES U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage.
SERIES If you find it hard to keep up with Facebook, LinkedIn, and other social networks, spare a thought for the brain. With 100 to 500 trillion synaptic connections, the human brain dwarfs all of them. How do those connections work to formulate thought, recall
SERIES Two weeks after the FDA gave the nod to aducanumab, the aftershocks continue to reverberate. Critics are lambasting the agency, three members of its advisory committee resigned, and the drug’s cost has ignited calls for pricing reform. Meanwhile, Alzheime
SERIES Have neuroscientists entered the era of the programmable brain? Thanks to optogenetics and pharmacogenetics, which let scientists switch neuronal activity on or off with light or designer drugs, scientists can now control specific subtypes of neurons in r
SERIES With the holidays upon us, are your nerves fraying under the combined pressures of work deadlines, shopping, decorating, and entertaining? Now may be a good time to sit back and consider the effects of stress on the brain. Stress per se is not a cause of
SERIES CRISPR Gene Editing—Poised to Revolutionize Neuroscience? Neuroscientists Probe CRISPR Transgenics and Treatment Paradigms
SERIES The endocytic receptor SORL1 has come to fruition both literally and figuratively. An interactive diagram of the 2,214 amino acid behemoth—filled with findings about hundreds of rare variants—is live for viewing on the Alzforum Mutations database. A handf
SERIES Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is b
PAPER Quiroz YT, Aguillon D, Aguirre-Acevedo DC, Vasquez D, Zuluaga Y, Baena AY, Madrigal L, Hincapié L, Sanchez JS, Langella S, Posada-Duque R, Littau JL, Villalba-Moreno ND, Vila-Castelar C, Ramirez Gomez L, Garcia G, Kaplan E, Rassi Vargas S, Ossa JA, Valderrama-Carmona P, Perez-Corredor P, Krasemann S, Glatzel M, Kosik KS, Johnson K, Sperling RA, Reiman EM, Sepulveda-Falla D, Lopera F, Arboleda-Velasquez JF
N Engl J Med. 2024 Jun 20;390(23):2156-2164. PubMed.
PAPER Lopera F, Arboleda-Velasquez JF
N Engl J Med. 2024 Oct 31;391(17):1661. PubMed. Original paper
PAPER Cochran JN, Greicius MD, Goate AM
N Engl J Med. 2024 Oct 31;391(17):1660-1661. PubMed. Original paper.
SERIES A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the Parkinson's Progression Markers Initiative (PPMI) follow
CONFERENCE 2025-02-05 00:00:00-2025-02-07 00:00:00 Bressone, Italy 05 – 07 February 2025 This event is organized by the Italian Society for Dementia (SINDEM) and is specifically tailored for junior researchers in the field of neurodegenerative diseases. The conference aims to provide a platform